Baxter Recalls Vasopressin Injection Due to Manufacturing Deviations
Baxter Healthcare is voluntarily recalling specific lots of Vasopressin in 0.9% Sodium Chloride Injection due to Current Good Manufacturing Practice (CGMP) deviations.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: The recall is classified as FDA Class II and involves a high-risk intravenous medication where the hazard (CGMP deviations) poses a risk of harm, but the source text does not report any specific illnesses or injuries.
Plain-English summary
Baxter Healthcare Corporation is voluntarily recalling specific lots of Vasopressin in 0.9% Sodium Chloride Injection, 20 units per 100 mL (0.2 units/mL), 100mL Single-Dose Container. The recall was initiated by the firm on August 6, 2026, and is classified as Class II by the FDA. The reason for the recall is identified as Current Good Manufacturing Practice (CGMP) deviations.
The affected product is distributed in the United States, Puerto Rico, and Chile. The specific lots subject to the recall are Lot # NC193672 and Lot # NC193795 (Expiration Date: 04/30/2028) and Lot # NC194198 (Expiration Date: 05/31/2028). The product is a prescription-only, sterile, intravenous injection.
Healthcare providers and patients should check their inventory and medication records for these specific lot numbers. If the product is found, it should be quarantined and not administered. The source text does not report any specific illnesses or injuries associated with this recall.
The recalled product
- Product
- VASOPRESSIN IN 0.9% SODIUM CHLORIDE (VASOPRESSIN IN 0.9% SODIUM CHLORIDE)
- Brand
- VASOPRESSIN IN 0.9% SODIUM CHLORIDE
- Manufacturer
- Baxter Healthcare Corporation
- Category
- Drug — Prescription Injection
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (5)
- Lot # NC193672
- NC193795
- Exp Date: 04/30/2028
- Lot # NC194198
- Exp Date: 05/31/2028.
Distribution
Related recalls
Same brand · VASOPRESSIN IN 0.9% SODIUM CHLORIDE
- SevereBaxter Recalls Vasopressin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
Same manufacturer · Baxter Healthcare Corporation
See all →- HighBaxter Recalls Vancomycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- SevereBaxter Recalls Daptomycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- ModerateBaxter Recalls Pantoprazole Sodium Infusion Bags Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- HighBaxter Recalls Clindamycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- HighBaxter Novum IQ Syringe Pump Recalled for Software Infusion Issue
FDA (Devices) · 2026-09-09
Same hazard · cgmp deviations
See all →- SevereBaxter Recalls Dexmedetomidine Hydrochloride Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- SevereBaxter Recalls Famotidine Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- SevereBaxter Recalls Nexterone Amiodarone Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- ModerateFentanyl Citrate Injectable Solution Recall Due to cGMP Deviations
FDA (Drugs) · 2026-05-06
- ModerateGlenmark Lacosamide 100mg Tablets Recalled for CGMP Deviations
FDA (Drugs) · 2025-04-16